These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 22930504)

  • 1. Hepatitis B e antigen predicts delayed reduction of HBV DNA without viral breakthrough with adefovir dipivoxil and lamivudine: a 5-year study of patients with hepatitis B with lamivudine resistance.
    Ikeda F; Baba N; Takaguchi K; Kubota J; Miyoshi K; Fujioka S; Moritou Y; Takeuchi Y; Yasunaka T; Miyake Y; Takaki A; Iwasaki Y; Kobashi H; Yamamoto K
    J Med Virol; 2012 Oct; 84(10):1562-70. PubMed ID: 22930504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients.
    Aizawa M; Tsubota A; Fujise K; Tatsuzawa K; Kono M; Hoshina S; Tajiri H
    J Med Virol; 2011 Jun; 83(6):953-61. PubMed ID: 21503906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients.
    Idilman R; Kaymakoglu S; Oguz Onder F; Ahishali E; Bektas M; Cinar K; Pinarbasi B; Karayalcin S; Badur S; Cakaloglu Y; Mithat Bozdayi A; Bozkaya H; Okten A; Yurdaydin C
    J Viral Hepat; 2009 Apr; 16(4):279-85. PubMed ID: 19222742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients.
    Buti M; Elefsiniotis I; Jardi R; Vargas V; Rodriguez-Frias F; Schapper M; Bonovas S; Esteban R
    J Hepatol; 2007 Sep; 47(3):366-72. PubMed ID: 17561304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
    Vassiliadis TG; Giouleme O; Koumerkeridis G; Koumaras H; Tziomalos K; Patsiaoura K; Grammatikos N; Mpoumponaris A; Gkisakis D; Theodoropoulos K; Panderi A; Katsinelos P; Eugenidis N
    J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.
    Lee YS; Suh DJ; Lim YS; Jung SW; Kim KM; Lee HC; Chung YH; Lee YS; Yoo W; Kim SO
    Hepatology; 2006 Jun; 43(6):1385-91. PubMed ID: 16729316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.
    Heo NY; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    J Hepatol; 2010 Sep; 53(3):449-54. PubMed ID: 20646776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
    Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
    Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
    Dai CY; Chuang WL; Hsieh MY; Lee LP; Huang JF; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Tsai JF; Chang WY; Yu ML
    Antiviral Res; 2007 Aug; 75(2):146-51. PubMed ID: 17400303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Core promoter mutant HBV non-responding to adefovir after viral breakthrough on lamivudine: rapid virologic response to tenofovir plus lamivudine in a cirrhotic patient.
    Katsounas A; Jochum C; Canbay A; Schlaak J; Gerlich WH; Gerken G
    Eur J Med Res; 2008 Oct; 13(10):472-5. PubMed ID: 19008175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
    Yang HJ; Lee JH; Kim YJ; Yoon JH; Lee HS
    J Med Virol; 2012 Mar; 84(3):424-30. PubMed ID: 22246827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.
    Yatsuji H; Suzuki F; Sezaki H; Akuta N; Suzuki Y; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Watahiki S; Iwasaki S; Kobayashi M; Kumada H
    J Hepatol; 2008 Jun; 48(6):923-31. PubMed ID: 18433925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.
    Patterson SJ; George J; Strasser SI; Lee AU; Sievert W; Nicoll AJ; Desmond PV; Roberts SK; Locarnini S; Bowden S; Angus PW
    Gut; 2011 Feb; 60(2):247-54. PubMed ID: 21036792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
    N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.
    Chen CH; Wang JH; Lu SN; Hu TH; Hung CH; Chang MH; Changchien CS; Lee CM
    Antivir Ther; 2012; 17(4):701-9. PubMed ID: 22358132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B.
    Kim SS; Cheong JY; Lee D; Lee MH; Hong SP; Kim SO; Cho SW
    J Med Virol; 2012 Jan; 84(1):18-25. PubMed ID: 22028068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern.
    Inoue J; Ueno Y; Wakui Y; Niitsuma H; Fukushima K; Yamagiwa Y; Shiina M; Kondo Y; Kakazu E; Tamai K; Obara N; Iwasaki T; Shimosegawa T
    J Viral Hepat; 2011 Mar; 18(3):206-15. PubMed ID: 20367795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance.
    Chen CH; Lee CM; Tung WC; Wang JH; Hung CH; Hu TH; Wang JC; Lu SN; Changchien CS
    J Hepatol; 2010 Apr; 52(4):478-85. PubMed ID: 20185198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.